Singapore's Synthetic Biology Moment: Building a Global Translation Hub

Synthetic biology has become one of the most exciting technology sectors of the past decade. Advances in gene editing, enzyme engineering, AI-guided protein design and industrial biomanufacturing are allowing researchers to harness biology in ways that would have seemed like science fiction only a few years ago.

The discussion around synthetic biology is often centred on the US, UK, and China. However, another ecosystem is quietly growing in both capability and ambition. Singapore is positioning itself as a global centre for SynBio research, translation and commercialisation.

Recent developments suggest that Singapore is not just building a strong academic research base; it is creating the infrastructure, talent and industrial partnerships needed to transform discoveries into commercially valuable technologies. For anyone interested in the future of synthetic biology and engineering biology, Singapore is a place worth watching.

A focus on translation, not just discovery

One of the challenges facing any emerging technology sector is bridging the gap between academic research and commercial deployment. While world-class science is essential, creating successful companies requires scale-up expertise, industrial partnerships, investment and intellectual property protection.

Singapore appears increasingly focused on addressing exactly this challenge. In June 2026, the A*STAR SIFBI-NUS Synthetic Biology Joint Lab was launched by the Agency for Science, Technology and Research (ASTAR) and the National University of Singapore (NUS). The initiative brings together ASTAR's strengths in bioprocess development and industrial translation with NUS's expertise in synthetic biology research

The launch of the Joint Lab reflects a broader trend within Singapore's innovation ecosystem. Rather than focusing solely on research outputs, increasing emphasis is being placed on moving technologies from the laboratory into real-world applications.

World-class synthetic biology research

Singapore's growing reputation in synthetic biology is built upon a strong research foundation. A major contributor to this success is NUS Synthetic Biology for Clinical and Technological Innovation (SynCTI), led by Professor Matthew Chang. SynCTI has established itself as one of Asia's leading synthetic biology centres, generating significant research outputs, intellectual property and spin-out activity across areas such as metabolic engineering, synthetic biology platforms, therapeutics and sustainable biomanufacturing.

The wider ecosystem also benefits from contributions from researchers such as Professor David Leong, whose exciting work spans biomaterials and translational bioengineering, and Dr Chueh Loo Poh, a long-standing leader within Singapore's synthetic biology community and an important figure in the development of collaborative initiatives such as SINERGY.

Importantly, these efforts are supported by a highly collaborative environment. Universities, government research institutes, investors and industry partners operate within a closely connected ecosystem that facilitates technology transfer and commercialisation.

Spin-outs, start-ups and industrial impact

Perhaps the strongest evidence of Singapore's progress is the quality of companies emerging from the ecosystem.

One prominent example is Allozymes, an NUS spin-out that has developed the ZymeLeap™ platform for ultra-high-throughput enzyme engineering. By combining microfluidics, computational methods and machine learning, the company can rapidly identify improved enzyme variants for applications ranging from industrial biotechnology to oligonucleotide therapeutics manufacturing.

In the sustainable manufacturing sector, Terra Oleo is applying synthetic biology and precision fermentation to develop alternatives to conventional palm oil ingredients and cocoa butter. Through engineered microbial production systems, the company aims to create more sustainable and resilient supply chains for ingredients used across food, cosmetics and consumer products.

Meanwhile, Insectta is demonstrating how biological innovation can support the circular economy. The company has developed proprietary technologies to extract valuable biomaterials such as chitosan and melanin from black soldier fly larvae, creating opportunities in industries ranging from cosmetics to advanced materials.

These companies represent only a small sample of the activity underway across Singapore's wider synthetic biology landscape. However, collectively they highlight a common theme: translating biological innovation into commercially valuable products and services.

Unlike larger ecosystems, Singapore's advantage is density rather than pure scale. Academics, researchers, investors, commercial leaders, and manufacturers often operate within the same network.  This really sets Singapore apart from competitor SynBio hubs.

Why Singapore matters

Taken together, Singapore is assembling many of the components needed for a successful synthetic biology ecosystem:

• World-class research institutions.

• Strong government support and long-term investment.

• Access to scale-up and bioprocessing expertise.

• Growing venture-backed start-up activity.

• A collaborative innovation culture.

• A clear focus on commercialisation and industry partnerships.

This combination is helping create an environment where synthetic biology technologies can move more efficiently from discovery to deployment.

As synthetic biology continues to mature, competitive advantage is increasingly determined not only by scientific excellence, but also by the ability to scale technologies, generate valuable intellectual property and bring products to market. Singapore appears well positioned in all three areas.

Looking ahead

Synthetic biology has the potential to transform how we manufacture chemicals, ingredients, pharmaceuticals, materials and consumer products. While innovation is occurring globally, Singapore is becoming increasingly notable for its ability to connect fundamental research with industrial application.

As Singapore's synthetic biology ecosystem continues to mature, intellectual property will remain a critical enabler of commercial success. Strong patent portfolios can help companies attract investment, establish strategic partnerships and create long-term competitive advantage At Mewburn Ellis, we work with a wide range of Singapore-based companies, research institutes and investors across the biotechnology, life sciences and synthetic biology sectors, supporting innovation from early-stage research through to fundraising, commercial partnerships, and successful exits.

The next generation of synthetic biology breakthroughs may emerge from many places around the world. Increasingly, however, Singapore looks likely to be one of the places where those breakthroughs are translated into impactful technologies, successful companies and valuable intellectual property. For anyone interested in the future of synthetic biology, engineering biology and the wider bioeconomy, Singapore's synthetic biology moment may only just be beginning.